Orchid Pharma Limited announced that its amalgamation scheme with Dhanuka Laboratories Limited is effective from July 10, 2026. Dhanuka Laboratories will be dissolved. The company has also increased its authorized share capital to ₹164.51 crore. A record date of July 23, 2026, has been set for share allocation.
Orchid Pharma and Dhanuka Laboratories Merger Now Effective
Orchid Pharma and Dhanuka Laboratories merger effective July 10, 2026. Authorized share capital increased to ₹164.51 crore.
Reader Takeaway: Merger completion signals integration; record date is key for shareholders.
What just happened
The Scheme of Amalgamation between Orchid Pharma Limited and Dhanuka Laboratories Limited has been declared effective from July 10, 2026. As part of this corporate action, Dhanuka Laboratories Limited has ceased to exist as a separate entity without undergoing liquidation.
The appointed date for this amalgamation was April 1, 2024, and the scheme's effectiveness date is July 10, 2026.
Why this matters
This signifies the formal closure of the merger process. Shareholders of Dhanuka Laboratories will now receive shares of Orchid Pharma based on a specific ratio. The company's authorized share capital has also been revised to accommodate the combined entity.
The backstory
The amalgamation process, initiated with an appointed date of April 1, 2024, has now reached its effective stage. This move is part of Orchid Pharma's strategic efforts to consolidate operations.
What changes now
Orchid Pharma has updated its Memorandum of Association to reflect an increased authorized share capital of ₹164.51 crore (₹164,51,00,000). This capital is divided into 16,45,10,000 equity shares, each with a face value of ₹10.
Risks to watch
Investors need to carefully track the share exchange process and ensure their holdings are updated accordingly. The operational integration of the two entities will be a key factor to monitor going forward.
Peer comparison
Mergers and acquisitions are common in the pharmaceutical sector as companies seek to achieve economies of scale and expand their product portfolios. This consolidation aims to strengthen Orchid Pharma's market position.
Context metrics (time-bound)
- Effective Date: July 10, 2026
- Record Date: July 23, 2026
- Appointed Date: April 1, 2024
- Share Exchange Ratio: 161:5 (Orchid Pharma : Dhanuka Laboratories)
- New Authorised Share Capital: ₹164.51 crore
- Face Value per share: ₹10
What to track next
Shareholders should note the record date of July 23, 2026, for the share swap. Monitoring the post-merger performance and integration progress of Orchid Pharma will be crucial for investors.